Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine.
IgG ELISpot
IgG subclasses
MERS-CoV
MVA-MERS-S
immune persistence
late booster vaccination
long-term immunity
memory B cells
neutralizing antibodies
viral vector vaccine
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
19 07 2022
19 07 2022
Historique:
received:
08
10
2020
revised:
25
02
2022
accepted:
16
06
2022
entrez:
20
7
2022
pubmed:
21
7
2022
medline:
23
7
2022
Statut:
ppublish
Résumé
The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies.
Identifiants
pubmed: 35858586
pii: S2666-3791(22)00221-X
doi: 10.1016/j.xcrm.2022.100685
pmc: PMC9295383
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Viral Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT03615911']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100685Investigateurs
Etienne Bartels
(E)
Swantje Gundlach
(S)
Thomas Hesterkamp
(T)
Verena Krähling
(V)
Susan Lassen
(S)
My Linh Ly
(ML)
Joseph H Pötsch
(JH)
Stefan Schmiedel
(S)
Asisa Volz
(A)
Madeleine E Zinser
(ME)
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Lancet Infect Dis. 2020 Jul;20(7):816-826
pubmed: 32325038
Nat Commun. 2014;5:3067
pubmed: 24473083
Clin Transl Immunology. 2021 Feb 28;10(3):e1258
pubmed: 33680466
Nat Commun. 2022 Jul 19;13(1):4182
pubmed: 35853863
Lancet Microbe. 2022 Jan;3(1):e11-e20
pubmed: 34751259
Lancet Infect Dis. 2014 Dec;14(12):1196-207
pubmed: 25455987
EMBO Mol Med. 2022 Mar 7;14(3):e15227
pubmed: 34994081
J Infect Dis. 2018 Jul 13;218(4):614-623
pubmed: 29912453
Lancet Infect Dis. 2019 Sep;19(9):1013-1022
pubmed: 31351922
Lancet HIV. 2020 Apr;7(4):e238-e248
pubmed: 32035516
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
Clin Infect Dis. 2021 Aug 2;73(3):e550-e558
pubmed: 32898238
Emerg Infect Dis. 2016 Jun;22(6):
pubmed: 27192543
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9081-6
pubmed: 27457935
Nat Commun. 2021 Apr 1;12(1):2037
pubmed: 33795692
Vaccine. 2006 Jan 30;24(5):572-7
pubmed: 16171909
Lancet Infect Dis. 2014 Jan;14(1):50-56
pubmed: 24239323
J Virol. 2013 Nov;87(21):11950-4
pubmed: 23986586
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Cell. 2020 Dec 10;183(6):1508-1519.e12
pubmed: 33207184
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12283-7
pubmed: 25136134
Nat Med. 2016 Jul 7;22(7):701-5
pubmed: 27387881
Immunology. 2018 Mar;153(3):279-289
pubmed: 29139548
Lancet Infect Dis. 2018 Aug;18(8):e217-e227
pubmed: 29680581
Trends Immunol. 2019 Mar;40(3):197-211
pubmed: 30745265
Nat Commun. 2021 Mar 17;12(1):1715
pubmed: 33731724
NPJ Vaccines. 2020 Mar 19;5(1):24
pubmed: 32218996
JCI Insight. 2020 Nov 5;5(21):
pubmed: 33031099
Front Microbiol. 2019 Aug 02;10:1781
pubmed: 31428074
Immunity. 1998 Mar;8(3):363-72
pubmed: 9529153
Immunity. 2010 Oct 29;33(4):451-63
pubmed: 21029957
Lancet. 2021 Jun 12;397(10291):2248
pubmed: 34119059
Lancet Infect Dis. 2020 Jul;20(7):827-838
pubmed: 32325037
Vaccine. 1996 Aug;14(11):1019-27
pubmed: 8879096
Expert Rev Vaccines. 2014 Jun;13(6):761-74
pubmed: 24766432
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Immunol Methods. 2012 Dec 14;386(1-2):117-23
pubmed: 23023091
Front Immunol. 2019 Oct 18;10:2458
pubmed: 31681331
Front Immunol. 2019 Mar 18;10:440
pubmed: 30949165
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Zoonoses Public Health. 2016 Feb;63(1):1-9
pubmed: 25545147
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Clin Microbiol Infect. 2022 Feb;28(2):292-296
pubmed: 34139334
mBio. 2020 Sep 25;11(5):
pubmed: 32978311
BMB Rep. 2019 Jun;52(6):397-402
pubmed: 30355437
Nat Med. 2021 Jun;27(6):1113
pubmed: 33958800
Sci Transl Med. 2014 Mar 19;6(228):228ra38
pubmed: 24648341